(Hypertension. 2001;38:1075.)
© 2001 American Heart Association, Inc.
Scientific Contributions |
2B-Adrenergic Receptor Messenger RNA in the Central Nervous System
From the Hypertension and Atherosclerosis Section, Department of Medicine, Boston University School of Medicine, Boston, Mass.
Correspondence to Haralambos Gavras, MD, Chief, Hypertension & Atherosclerosis Section, Boston University School of Medicine, 715 Albany St, Boston, MA 02118. E-mail hgavras{at}bu.edu
Abstract The results of previous studies with genetically engineered mice have suggested that an intact central
2B-adrenergic receptor (
2B-AR) subtype mediates the development and maintenance of salt-induced hypertension. In the present study, we sought to further define the role of this receptor by injecting antisense oligodeoxynucleotides (AS-ODNs), targeting a selected sequence of the
2B-AR mRNA, into the lateral cerebral ventricle of rats that had undergone prior subtotal nephrectomy and dietary salt loading. Cell culture studies showed that these AS-ODNs could block
2B-AR protein generation. Before AS-ODN injection, blood pressure (BP) averaged 133±5 mm Hg during the daytime and rose to 165±4 mm Hg during the nighttime activity hours (P<0.001 versus baseline average of 120±2 mm Hg). The injection of AS-ODNs during the early afternoon prevented the BP rise and was associated with a significant fall in heart rate (from 385±12 to 306±15 bpm, P<0.05) and symptoms of sedation that lasted for several hours, with a peak at 3 to 6 hours and full recovery by 24 hours. At that time, a second injection produced identical effects in all rats (n=9). Control rats (n=10) that received scrambled ODN injections had no changes in BP or heart rate patterns, and neither group had evidence of neurotoxicity, indicating that these effects are specifically due to translational inhibition of central
2B-AR. We conclude that a fully functional central
2B-AR is necessary for the induction of salt-dependent hypertension.
Key Words: hypertension, sodium dependent genes antihypertensive therapy
This article has been cited by other articles:
![]() |
L. C. Duling, T. W. Cherng, J. R. Griego, M. F. Perrine, and N. L. Kanagy Loss of {alpha}2B-adrenoceptors increases magnitude of hypertension following nitric oxide synthase inhibition Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2403 - H2408. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Plut, C. Ribiere, Y. Giudicelli, and J.-P. Dausse Gender Differences in Hypothalamic Tyrosine Hydroxylase and alpha 2-Adrenoceptor Subtype Gene Expression in Cafeteria Diet-Induced Hypertension and Consequences of Neonatal Androgenization J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 525 - 531. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Philipp, M. Brede, and L. Hein Physiological significance of alpha 2-adrenergic receptor subtype diversity: one receptor is not enough Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2002; 283(2): R287 - R295. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. A. Janssen and J. F. M. Smits Autonomic control of blood pressure in mice: basic physiology and effects of genetic modification Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2002; 282(6): R1545 - R1564. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |